TY  - CONF
AU  - Owonikoko, T. K.
AU  - Kim, H. R.
AU  - Govindan, R.
AU  - Ready, N.
AU  - Reck, M.
AU  - Peters, S.
AU  - Dakhil, S. R.
AU  - Navarro, A.
AU  - Rodriguez-Cid, J.
AU  - Schenker, M.
AU  - Lee, J. S.
AU  - Gutierrez, V.
AU  - Percent, I.
AU  - Morgensztern, D.
AU  - Fairchild, J.
AU  - Baudelet, C.
AU  - Park, K.
PY  - 2019
DO  - 10.1093/annonc/mdz094
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/24385
T2  - Annals of oncology
LA  - en
PB  - Oxford univ press
TI  - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
TY  - conference output
VL  - 30
ER  -